The application of these bioplatforms to the analysis of cohorts of healthy individuals and patients diagnosed with cancer and Alzheimer disease (AD) showed the usefulness of new characteristic signatures comprising AAbs against eight circulating tumor antigens [24], fifteen exosomal tumor antigens (Fig. 5) [25], or four proteoforms of p53 and p63 proteins [26], for the early diagnosis of patients with CRC and premalignant lesions of this neoplasm, as well as the signature involving AAbs against six peptides (four phage-deployed and two aberrant) for preclinical identification of AD [27]. This evidence concerns the gene TP53 and colorectal carcinoma.